• Please log in or register to access this feature.

Research Article

You have full text access to this OnlineOpen article

Suppressed Bone Turnover by Long-Term Bisphosphonate Treatment Accumulates Microdamage but Maintains Intrinsic Material Properties in Cortical Bone of Dog Rib†

  1. Satoshi Komatsubara1,
  2. Satoshi Mori1,*,
  3. Tasuku Mashiba1,
  4. Jilliang Li1,2,
  5. Kiichi Nonaka3,
  6. Yoshio Kaji1,
  7. Tomoyuki Akiyama1,
  8. Kensaku Miyamoto1,
  9. Yongping Cao1,
  10. Jun Kawanishi1,
  11. Hiromichi Norimatsu1

Article first published online: 19 JAN 2004

DOI: 10.1359/JBMR.040126

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 19, Issue 6, pages 999–1005, June 2004

Additional Information

How to Cite

Komatsubara, S., Mori, S., Mashiba, T., Li, J., Nonaka, K., Kaji, Y., Akiyama, T., Miyamoto, K., Cao, Y., Kawanishi, J. and Norimatsu, H. (2004), Suppressed Bone Turnover by Long-Term Bisphosphonate Treatment Accumulates Microdamage but Maintains Intrinsic Material Properties in Cortical Bone of Dog Rib. J Bone Miner Res, 19: 999–1005. doi: 10.1359/JBMR.040126

Author Information

  1. 1

    Department of Orthopedic Surgery, Kagawa University, Kagawa, Japan

  2. 2

    Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA

  3. 3

    Section of Pharmacology, Department of Hard Tissue Engineering, Division of Bio-Matrix, Tokyo Medical Dental University, Tokyo, Japan

*Address reprint requests to: Satoshi Mori, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan

  1. †

    The authors have no conflict of interest

Publication History

  1. Issue published online: 2 DEC 2009
  2. Article first published online: 19 JAN 2004
  3. Manuscript Accepted: 19 JAN 2004
  4. Manuscript Revised: 29 DEC 2003
  5. Manuscript Received: 4 MAY 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (476K)

REFERENCES

  • 1
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk if fracture in women with existing vertebral fractures: Fracture Invention Trial research group. Lancet 348: 1535–1541.
  • 2
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCorix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Invention Trial. JAMA 280: 2077–2082.
  • 3
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11: 83–91.
  • 4
    Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB 1997 Treatment with alendronate prevents fractures in women at higher risk: Results from the fracture intervention trial. Arch Intern Med 157: 2617–2624.
  • 5
    Fleisch H 1997 Bisphosphonate: Preclinical aspects and use in osteoporosis. Ann Med 29: 55–62.
  • 6
    Karpf DB, Shaprio DR, Seemann E, Ensrud KE, Johnston CC Jr, Adami S, Harris ST, Santona ACN, Hirsch LJ, Oppenheimer L, Thompson D 1997 Prevention of nonvertebral fractures by alendronate: A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 277: 1159–1164.
  • 7
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282: 1344–1352.
  • 8
    Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27: 687–694.
  • 9
    Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 1475–1480.
  • 10
    Burr DB, Forwood MR, Fyhrie DP, Martin RB, Shaffler MB, Turner CH 1997 Bone microdamage and skeletal fragility in osteoporosis and stress fracture. J Bone Miner Res 12: 6–15.
  • 11
    Frost HM 1998 A brief review for orthopedic surgeons: Fatigue damage (microdamage) in bone (its determinants and clinical implications). J Orthop Sci 3: 272–281.
  • 12
    Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Does suppression of bone turnover cause loss of mechanical properties by allowing microdamage to accumulate? Bone 27: 13–20.
  • 13
    Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB 2001 Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524–531.
  • 14
    Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Suppressed bone turnover by bisphosphonates increase microdamage accumulation and reduce some biomechanical properties in dog rib. J Bone Miner Res 15: 613–620.
  • 15
    Komatsubara S, Mori S, Mashiba T, Ito M, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H 2002 Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18: 512–520.
  • 16
    Fleish H 2000 Bisphosphonate in bone disease. In: From the Laboratory to Patient, 4th ed. Academic Press, San Diego, CA, USA, pp. 30–33.
  • 17
    Tamura Y, Miyakoshi N, Itoi E, Abe T, Kudo T, Tsuchida T, Kasukawa Y, Sato K 2001 Long-term effects of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover, in the lumbar vertebrae of ovariectomized rats. J Bone Miner Res 16: 541–549.
  • 18
    Motoie H, Nakamura T, O'uchi N, Nishikawa H, Kanoh H, Abe T, Kawashima H 1995 Effects of bisphosphonates YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction. J Bone Miner Res 10: 910–920.
  • 19
    Li J, Mori S, Mashiba T, Kaji Y, Taki M, Komatsubara S, Kawanishi J, Norimatsu H 1998 Preadministration on incadronate disodium can prevent bone loss in rat proximal tibial metaphysis when induced by hindlimb immobilization by bandage. Bone 23: 459–463.
  • 20
    Usui T, Watanabe T, Higuchi S 1992 Determination of new bisphosphonate, YM175, in plasma, urine, and body by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci 584: 213–220.
  • 21
    Burr DB, Stafford BS 1990 Validity of bulk-staining technique to separate artificial from in vivo bone microdamage. Clin Orthop 260: 305–308.
  • 22
    Burr DB, Hooser M 1995 Alterations to the en block basic fuchsin staining protocol for the demonstration of microdamage produced in vivo. Bone 17: 431–433.
  • 23
    Parfitt AM, Drezner MK, Glorieux MK, Kanis FH, Malluche JA, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 21: 595–610.
  • 24
    Foldes J, Shih MS, Parfitt AM 1990 Frequency distributions of tetracycline-based measurements: Implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J Bone Miner Res 5: 1063–1067.
  • 25
    Wenzel TE, Schaffler MB, Fyhrie DP 1996 In vivo trabecular microcracks in human vertebral bone. Bone 19: 89–95.
  • 26
    Mori S, Harruff R, Ambrosius W, Burr DB 1997 Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone 21: 521–526.
  • 27
    Mori S, Li J, Kawaguchi Y 2001 The histological appearance of stress fracture. In: BurrDB, MilgromC (eds.) Musculoskeletal Fatigue and Stress Fractures. CRC Press, New York, NY, USA, pp. 151–159.
  • 28
    Turner CH, Burr DB 1993 Basic biomechanical measurements of bone: A tutorial. Bone 14: 595–608.
  • 29
    Ott SM, Oleksik A, Lu Y, Harper K, Lips P 2002 Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 17: 341–348.
  • 30
    Fleish H 2000 Bisphosphonate in bone disease. In: From the Laboratory to Patient, 4th ed. Academic Press, San Diego, CA, USA, pp. 56–62.
  • 31
    Usui T, Watanabe T, Higuchi S 1995 Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs. Drug Metab Dispos 23: 1214–1219.
View Full Article (HTML) Get PDF (476K)